Skip to main content
SpringerLink
Log in

Other Precipitating Factors for AECHB

  • Chapter
  • First Online:
Acute Exacerbation of Chronic Hepatitis B

Abstract

This chapter describes the precipitating factors involved in AECHB and HBV ACLF, including discussion of gender, age, underlined chronic diseases other than CHB, intestinal microencology, liver fibrosis/cirrhosis, and HCC.

  1. 1.

    Several host factors, including gender, age, underlying diseases (such as fatty liver disease, diabetes, hyperthyroidism, connective tissue disease, pregnancy, and surgery), may influence the occurrence and development of severe hepatitis B.

  2. 2.

    Functional damage to the intestinal barrier and changes in microecology may excessively activate the immune system, aggravate liver cell apoptosis and necrosis, and promote the development of severe hepatitis B and its complications.

  3. 3.

    Liver fibrosis and cirrhosis have a major effect on the development of severe hepatitis B. Pathological changes in liver fibrosis, abnormal hemodynamics, liver immune state and complication scan all affect the occurrence, development and prognosis of severe chronic hepatitis B.

  4. 4.

    HBV progression, complications of liver cancer, treatment related damage, and HBV reactivation all can cause progressive liver damage, leading to the exacerbation of chronic hepatitis B, and have a negative effect on patient’s prognosis.

  5. 5.

    Co-infection with other pathogens (especially other hepadnaviruses) is the most frequent factor inducing severe hepatitis B. Various hepatotoxins (including chemicals, toxins, alcohol, and drugs) can cause severe hepatitis B.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut. 2010;59:1561–9.

    Article  Google Scholar 

  2. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol. 2012;57:1336–48.

    Article  Google Scholar 

  3. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437, 1437 e1421–1429.

    Article  Google Scholar 

  4. Verbeke L, Nevens F, Laleman W. Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. Crit Care. 2011;15:233.

    Article  Google Scholar 

  5. Baohong W, Mingfei Y, Zongxin L, Lanjuan L. The human microbiota in health and disease. Engineering. 2017;3(1):71–82.

    Article  Google Scholar 

  6. Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6:32002.

    Article  CAS  Google Scholar 

  7. Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010;53:849–55.

    Article  Google Scholar 

  8. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–72.

    Article  Google Scholar 

  9. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940–7.

    Article  CAS  Google Scholar 

  10. Chen Y, Guo J, Qian G, Fang D, Shi D, Guo L, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol. 2015;30:1429–37.

    Article  CAS  Google Scholar 

  11. Osman N, Adawi D, Ahrne S, Jeppsson B, Molin G. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig Liver Dis. 2007;39:849–56.

    Article  CAS  Google Scholar 

  12. Chen C, Li L, Wu Z, Chen H, Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect. 2007;54:98–102.

    Article  Google Scholar 

  13. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64.

    Article  CAS  Google Scholar 

  14. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–3.

    Article  CAS  Google Scholar 

  15. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4.

    Article  CAS  Google Scholar 

  16. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.

    Article  CAS  Google Scholar 

  17. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.

    Article  CAS  Google Scholar 

  18. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688–93.

    Article  Google Scholar 

  19. Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015;16:7493–519.

    Article  CAS  Google Scholar 

  20. Janssen AW, Kersten S. The role of the gut microbiota in metabolic health. FASEB J. 2015;29:3111–23.

    Article  CAS  Google Scholar 

  21. Krajmalnik-Brown R, Ilhan ZE, Kang DW, DiBaise JK. Effects of gut microbes on nutrient absorption and energy regulation. Nutr Clin Pract. 2012;27:201–14.

    Article  Google Scholar 

  22. Li YT, Wang L, Chen Y, Chen YB, Wang HY, Wu ZW, et al. Effects of gut microflora on hepatic damage after acute liver injury in rats. J Trauma. 2010;68:76–83.

    Article  Google Scholar 

  23. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A. 2008;105:2117–22.

    Article  CAS  Google Scholar 

  24. Chou HH, Chien WH, Wu LL, Cheng CH, Chung CH, Horng JH, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci U S A. 2015;112:2175–80.

    Article  CAS  Google Scholar 

  25. Wang B, Li L. Who determines the outcomes of HBV exposure? Trends Microbiol. 2015;23:328–9.

    Article  CAS  Google Scholar 

  26. Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, Zlabinger GJ. n-Butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology. 1997;92:234–43.

    Article  CAS  Google Scholar 

  27. Ray K. Gut microbiota: obesity-induced microbial metabolite promotes HCC. Nat Rev Gastroenterol Hepatol. 2013;10:442.

    Article  Google Scholar 

  28. Ren YD, Ye ZS, Yang LZ, Jin LX, Wei WJ, Deng YY, et al. Fecal microbiota transplantation induces HBeAg clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology. 2017;65(5):1765–8.

    Article  Google Scholar 

  29. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia. 2010;53:606–13.

    Article  CAS  Google Scholar 

  30. Xu M, Wang B, Fu Y, Chen Y, Yang F, Lu H, et al. Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease. Microb Ecol. 2012;63:304–13.

    Article  Google Scholar 

  31. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61:693–703.

    Article  Google Scholar 

  32. Wei X, Yan X, Zou D, Yang Z, Wang X, Liu W, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol. 2013;13:175.

    Article  Google Scholar 

  33. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303:G675–85.

    Article  CAS  Google Scholar 

  34. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303(6):G675–85.

    Article  CAS  Google Scholar 

  35. Chen Y, Ji F, Guo J, Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep. 2016;6:34055.

    Article  CAS  Google Scholar 

  36. Rakoff-Nahoum S, Medzhitov R. Innate immune recognition of the indigenous microbial flora. Mucosal Immunol. 2008;1(Suppl 1):S10–4.

    Article  CAS  Google Scholar 

  37. Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62:1260–71.

    Article  CAS  Google Scholar 

  38. Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs. 2000;60:1353–70.

    Article  CAS  Google Scholar 

  39. Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation. Nature. 2015;525:E1–2.

    Article  CAS  Google Scholar 

  40. Liu J, Wu D, Ahmed A, Li X, Ma Y, Tang L, et al. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Curr Microbiol. 2012;65:7–13.

    Article  CAS  Google Scholar 

  41. Ling Z, Liu X, Cheng Y, Jiang X, Jiang H, Wang Y, et al. Decreased diversity of the oral microbiota of patients with hepatitis B virus-induced chronic liver disease: a pilot project. Sci Rep. 2015;5:17098.

    Article  CAS  Google Scholar 

  42. Bajaj JS, Kakiyama G, Savidge T, Takei H, Kassam ZA, Fagan A, et al. Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology. 2018;68(3):1205.

    Article  Google Scholar 

  43. Li L, Wu Z, Ma W, Yu Y, Chen Y. Changes in intestinal microflora in patients with chronic severe hepatitis. Chin Med J. 2001;114:869–72.

    CAS  PubMed  Google Scholar 

  44. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–14.

    Article  Google Scholar 

  45. Ezendam J, van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev. 2006;64:1–14.

    Article  Google Scholar 

  46. Huang YF, Liu PY, Chen YY, Nong BR, Huang IF, Hsieh KS, et al. Three-combination probiotics therapy in children with salmonella and rotavirus gastroenteritis. J Clin Gastroenterol. 2014;48:37–42.

    Article  Google Scholar 

  47. Gevers D, Danielsen M, Huys G, Swings J. Molecular characterization of tet(M) genes in lactobacillus isolates from different types of fermented dry sausage. Appl Environ Microbiol. 2003;69:1270–5.

    Article  CAS  Google Scholar 

  48. Loguercio C, Federico A, Tuccillo C, Terracciano F, D’Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540–3.

    Article  Google Scholar 

  49. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011;23:725–32.

    Article  CAS  Google Scholar 

  50. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2010;22:199–206.

    Article  Google Scholar 

  51. Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition. 2011;27:177–81.

    Article  CAS  Google Scholar 

  52. Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147:1327–37. e1323

    Article  CAS  Google Scholar 

  53. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2):S129–34.

    Article  Google Scholar 

  54. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttorp MJ, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess. 2011, 22(200):1–645.

    Google Scholar 

  55. Donohue DC. Safety of probiotics. Asia Pac J Clin Nutr. 2006;15:563–9.

    CAS  PubMed  Google Scholar 

  56. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651–9.

    Article  Google Scholar 

  57. Yi P, Li L. The germfree murine animal: an important animal model for research on the relationship between gut microbiota and the host. Vet Microbiol. 2012;157:1–7.

    Article  Google Scholar 

  58. Brugman S, Schneeberger K, Witte M, Klein MR, van den Bogert B, Boekhorst J, et al. T lymphocytes control microbial composition by regulating the abundance of Vibrio in the zebrafish gut. Gut Microbes. 2014;5:737–47.

    Article  Google Scholar 

  59. Clark LC, Hodgkin J. Commensals, probiotics and pathogens in the Caenorhabditis elegans model. Cell Microbiol. 2014;16:27–38.

    Article  CAS  Google Scholar 

  60. Ke WM, Li XJ, Yu LN, et al. Etiological investigation of fatal liver failure during the course of chronic hepatitis B in south East China. J Gastroenterol. 2006;41(4):347–51.

    Article  Google Scholar 

  61. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283(5405):1183–6.

    Article  CAS  Google Scholar 

  62. Maini MK, Boni C, Lee CK, et al. The role of virus specific CD8 (+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191(8):1269–80.

    Article  CAS  Google Scholar 

  63. Kumar S, Ratho RK, Chaw La YK, et al. Virological investigation of a hepatitis epidemic in North India. Singapore Med J. 2006;47(9):769–73.

    CAS  PubMed  Google Scholar 

  64. Nusret A, Seyfettin Y, Ahmet G. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol. 2005;11(21):3260–3.

    Article  Google Scholar 

  65. Husa P, Linhartová A, Nemecek V, et al. Hepatitis D. Acta Virol. 2005;49:219–25.

    CAS  PubMed  Google Scholar 

  66. Canovic P, Gajovic O, Todorovic Z, et al. Epstein-Barr virus hepatitis associated with icterus a case report. Med Pregl. 2006;59(3):179–82.

    Article  Google Scholar 

  67. Jeffrey I. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–92.

    Article  Google Scholar 

  68. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver related mortality in the Multicenter Cohort Study (MACS) [J]. Lancet. 2002;360:1921–6.

    Article  Google Scholar 

  69. Gómez-Gonzalo M, Carretero M, Rullas J, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem. 2001;276(38):35435–43.

    Article  Google Scholar 

  70. Nunez M, Sariano V. Management of patients coinfected with hepatitis B virus and HIV. Lancet Infect Dis. 2005;5:374–82.

    Article  CAS  Google Scholar 

  71. Aizawa Y, Jing YH. Antibacterial drugs and drug-induced liver injury. Prog Jpn Med. 2006;27(6):267–9. (in Chinese)

    Google Scholar 

  72. Nakamoto N, You LR. Antineoplastic-induced liver injury. Prog Jpn Med. 2006;27(6):253–5. (in Chinese)

    Google Scholar 

  73. Letschert K, Faulstich H, Keller D, et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006;91:140–9.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Bao-Hong Wang and Jing Guo contributed equally to this work.

Authors and Affiliations

  1. National Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

    Bao-Hong Wang, Jing Guo & Lan-Juan Li

  2. Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Tao Chen

  3. Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Chun-Xia Guo & Yong-Wen He

Authors
  1. Bao-Hong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lan-Juan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chun-Xia Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yong-Wen He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lan-Juan Li or Lan-Juan Li .

Editor information

Editors and Affiliations

  1. Department of Infectious Disease, Tongji Hospital, Wuhan, China

    Qin Ning

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature B.V. and Huazhong University of Science and Technology Press

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wang, BH., Guo, J., Li, LJ., Chen, T., Guo, CX., He, YW. (2019). Other Precipitating Factors for AECHB. In: Ning, Q. (eds) Acute Exacerbation of Chronic Hepatitis B. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-1606-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-024-1606-0_6

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-024-1604-6

  • Online ISBN: 978-94-024-1606-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation